NCT07455058
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Recruiting
Not specifiedAll AgesObservationalFrancis Medical Inc.
~2,500 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Vanquish Therapy
At a glance
Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Efficacy Outcome
Measured over Through study completion, or up to 15 years.
+1 more outcome measured
Conditions
Where it's being run
2 sites across 2 statesTexas1
Virginia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Candidate for Vanquish therapy per physician discretion or participant has completed a company-sponsored Vanquish therapy study.
Participant is willing and able to provide written informed consent.
Exclusion
Contraindications per the Vanquish IFU
Previously participated in VAPOR 2 study and is not planning to receive further Vanquish therapy.
What this trial measures
- Primary Efficacy OutcomeThrough study completion, or up to 15 years.
Freedom from disease specific mortality.
- Primary Safety OutcomeThrough study completion, or up to 15 years
Rate of complications classified as Clavien-Dindo grades III-V and attributable to the Vanquish procedure and/or device over time. * Grade III: Complications requiring surgical intervention (IIIa: laparoscopic, IIIb: open). * Grade IV: Life-threatening complications (IVa: single organ failure, IVb: multi-organ failure). * Grade V: Death of a patient.